- Home
- ONDS vs ZNTL Comparison
ONDS vs ZNTL Comparison
Compare ONDS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- ZNTL
- Stock Information
- Founded
- ONDS 2014
- ZNTL 2014
- Country
- ONDS United States
- ZNTL United States
- Employees
- ONDS N/A
- ZNTL N/A
- Industry
- ONDS Telecommunications Equipment
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- ZNTL Health Care
- Exchange
- ONDS Nasdaq
- ZNTL Nasdaq
- Market Cap
- ONDS 102.0M
- ZNTL 102.2M
- IPO Year
- ONDS N/A
- ZNTL 2020
- Fundamental
- Price
- ONDS $0.86
- ZNTL $1.18
- Analyst Decision
- ONDS Strong Buy
- ZNTL Buy
- Analyst Count
- ONDS 2
- ZNTL 8
- Target Price
- ONDS $3.25
- ZNTL $8.53
- AVG Volume (30 Days)
- ONDS 5.1M
- ZNTL 763.9K
- Earning Date
- ONDS 05-15-2025
- ZNTL 05-27-2025
- Dividend Yield
- ONDS N/A
- ZNTL N/A
- EPS Growth
- ONDS N/A
- ZNTL N/A
- EPS
- ONDS N/A
- ZNTL N/A
- Revenue
- ONDS $7,192,694.00
- ZNTL $67,425,000.00
- Revenue This Year
- ONDS $256.61
- ZNTL N/A
- Revenue Next Year
- ONDS $104.92
- ZNTL N/A
- P/E Ratio
- ONDS N/A
- ZNTL N/A
- Revenue Growth
- ONDS N/A
- ZNTL N/A
- 52 Week Low
- ONDS $0.54
- ZNTL $1.01
- 52 Week High
- ONDS $3.40
- ZNTL $13.24
- Technical
- Relative Strength Index (RSI)
- ONDS 52.44
- ZNTL 37.08
- Support Level
- ONDS $0.76
- ZNTL $1.33
- Resistance Level
- ONDS $0.80
- ZNTL $1.33
- Average True Range (ATR)
- ONDS 0.06
- ZNTL 0.09
- MACD
- ONDS 0.02
- ZNTL -0.00
- Stochastic Oscillator
- ONDS 73.13
- ZNTL 0.00
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.